The biotech agency Agenesis recently announced the planting of a pig kidney in its second human patient. Through the progress of gene-editing and cloning, human organs transplant or genotransplant were possible from these animals.
Inadequate human kidneys to meet the demand for replacement, Agenesis and other companies are aims to help stop the interval with CRISPR-Cass 9, a gene-editing technology that won Nobel Prize in 2020 ChemistryThe
Genotransplant surgery
Editing a pig genome to remove the target sequences of the pig DNA and insert specific sequences of human DNA, Agenesis says that it can reduce the limbs and reduce the risk of cross-specific infections.
“Some people have the misconception that we edit adult animals. We do not do. We edit the cells and then we can produce adult animals from cells,” said Mike Curtis, President and CEO of Agenesis.
Donor animals are raised in a highly controlled environment to reduce the risk of moving towards any pathogens.
Curtis has told me that agemen is planning a number of additional transplants this year, with the aim of completing a trial of about 50 patients, then the company is expecting enough data to be more widely available.
Genotransplant recipient Tim is leaving the Andrews Hospital.
As the genotransplant recipient Team Andrews, he was his new kidney for almost two months and the latest word in Adnesses was doing well.
For our more coverage on agenesis and genotransplants, watch the video in this article.